title: Preparation and characterization of liposomal systems entrapping the boronated compound o-carboranylpropylamine.
abstract: Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when the stable isotope, Boron-10, is irradiated with low-energy thermal neutrons to yield ionizing Helium and Lithium ions that are highly damaging and usually lethal to cells. The successful treatment of cancer by BNCT requires the selective concentration of Boron-10 within malignant tumours. Liposomes have been used as therapeutic compound delivery vehicles for in vivo application, including several anticancer agents. The ability of the boron-containing compound, o-carboranylpropylamine chloride, to accumulate within unilamellar liposomes in response to a transmembrane pH gradient is evaluated. Characterization of the systems obtained is performed for conventional and polyethylene glycol (PEG)-modified (stealth) liposomes, in terms of lipid and CPA contents, vesicle size and stability in detergent solutions. Results demonstrate that CPA loading and vesicle stability can be controlled by the experimental procedure. The loading of CPA into liposomes with average diameters of 100 nm is estimated at 13000 molecules per vesicle for the most stable systems. CPA toxicity to normal human peripheral blood lymphocytes and to adherent glioblastoma multiforme SK-MG-1 cells in vitro is observed to decrease as a result of the entrapment of CPA in liposomes.
authors.affiliation: Department Processos Biotechnológicos/FEQ/State University of Campinas (UNICAMP), Cidade Universitária Zeferino Vaz, SP, Brazil. ammoraes@feq.unicamp.br
authors.forename: A M
authors.initials: AM
authors.lastname: Moraes
authors.forename: M H
authors.initials: MH
authors.lastname: Santana
authors.forename: R G
authors.initials: RG
authors.lastname: Carbonell
mesh_terms: D001896:Boron Compounds / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000633:toxicity; D016754:Boron Neutron Capture Therapy; D002448:Cell Adhesion; D003902:Detergents / Q000737:chemistry; D004355:Drug Stability; D004356:Drug Storage; D005909:Glioblastoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007554:Isotopes; D008081:Liposomes; D008214:Lymphocytes / Q000187:drug effects; D010713:Phosphatidylcholines / Q000737:chemistry / Q000378:metabolism; D010714:Phosphatidylethanolamines / Q000737:chemistry / Q000378:metabolism; D011092:Polyethylene Glycols / Q000737:chemistry / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D001896:Boron Compounds; D003902:Detergents; D007554:Isotopes; D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; C402177:o-carboranylpropylamine; D011092:Polyethylene Glycols; C010942:1,2-distearoyllecithin; C018525:1,2-dimyristoylphosphatidylethanolamine